Akkermansia Muciniphilia and Metabolic Side Effects of ADT

The overriding objectives of this study are: 1. Primary outcomes: 1. To confirm that administration of oral acetate increases the proportion of A. muciniphilia in the stool samples of patients with metastatic, castration-sensitive prostate cancer compared to a standard of care arm. 2. To confirm tolerability and assess for side effects of oral acetate supplementation. 2. Secondary outcomes: 1. To determine if increased counts of A. muciniphilia correlate with improved metabolic parameters and improved bone health.

NCT Number	NCT05802121
Lead Sponsor	Western University
Conditions	Prostate Cancer, Metabolic Syndrome, Obesity, Cardiovascular Morbidity, Bone Diseases, Hyperlipidemias, Diabetes
Enrollment	30 participants
Start Date	2025-07-02
Primary Completion	2026-09 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-08-20